Aggressive cancers and embryonic stem (ES) cells share a common gene expression signature. Identifying the key factors/ pathway(s) within this ES signature responsible for the aggressiveness of cancers can lead to a potential cure. In this study, we find that SALL4, a gene involved in the maintenance of ES cell self-renewal, is aberrantly expressed in 47.7% of primary human endometrial cancer samples. It is not expressed in normal or hyperplastic endometrial. More importantly, SALL4 expression is positively correlated with worse patient survival and aggressive features such as metastasis in endometrial carcinoma. Further functional studies have shown that loss of SALL4 inhibits endometrial cancer cell growth in vitro and tumorigenicity in vivo, as a result of inhibition of cell proliferation and increased apoptosis. In addition, downregulation of SALL4 significantly impedes the migration and invasion properties of endometrial cancer cells in vitro and their metastatic potential in vivo. Furthermore, manipulation of SALL4 expression can affect drug sensitivity of endometrial cancer cells to carboplatin. Moreover, we show that SALL4 specifically binds to the c-Myc promoter region in endometrial cancer cells. While downregulation of SALL4 leads to a decreased expression of c-Myc at both protein and mRNA levels, ectopic SALL4 overexpression causes increased c-Myc protein and mRNA expression, indicating that c-Myc is one of the SALL4 downstream targets in endometrial tumorigenesis. In summary, we are the first to demonstrate that SALL4 has functional role(s) in metastasis and drug resistance in aggressive endometrial cancer. As a consequence of its functional roles in cancer cell and absence in normal tissue, SALL4 is a potential novel therapeutic target for the high-risk endometrial cancer patient population.
INTRODUCTION
Endometrial carcinoma is the most common gynecological malignancy in the world. According to the National Cancer Institute, there are 8010 deaths from endometrial cancer in the United States in 2012. Although most patients (80%) can be surgically cured with a hysterectomy, the remaining 20% patients who are diagnosed with advanced or recurrent disease have far worse survival rates and limited adjuvant treatment options. 1, 2 Discovery of novel target(s)/pathway(s) is needed for better understanding of the pathogenesis and treatment development for this disease. Recent studies have shown that aggressive tumor cells share a common gene expression signature with embryonic stem (ES) cells. 3, 4 In these studies, SALL4 has been identified as one of the top-ranked genes enriched in high-grade cancers. As a transcription factor, SALL4 is known for its essential role in early embryonic development, and Sall4 null mice die shortly after implantation. 5, 6 Similar to OCT4, SOX2 and NANOG, SALL4 is essential to maintain ES cells in a self-renewal and undifferentiated state. By using a transgenic murine model, we previously reported that SALL4 can function as an oncogene in leukemogenesis. 7 Thereafter, its aberrant expression in germ cell tumors and other solid tumors has been reported by various groups. [8] [9] [10] However, in-depth studies on the functional role(s) of SALL4 in tumorigenesis of uterine tumors are still lacking.
In this study, by screening SALL4 expression in a cohort of endometrial cancer samples, we find that SALL4 is aberrantly expressed in endometrial cancer patient samples when compared with normal controls. More importantly, high SALL4 expression is significantly correlated with worse patient survival and metastasis capacity. Using human endometrial cancer cell lines, we have further conducted extensive investigations on the biological role of SALL4 in endometrial carcinogenesis. Both our in vitro and in vivo data strongly suggest that SALL4 expression is essential in endometrial cancer survival and progression, which is achieved by promoting tumor metastasis and chemoresistance. This mechanism of SALL4 in endometrial cancer is mediated, at least in part, through activation of c-Myc. Taken together, our studies hold potential promise on targeting SALL4 as a novel therapeutic option for endometrial cancer patients, especially those with advanced or recurrent disease. endometrial tissues. The data are summarized in Table 1 and Supplementary Table S1 , and representative images are shown in Figure 1a and Supplementary Figure S1 . In addition, we also evaluated SALL4 mRNA expression in endometrial cancers. Using snap-frozen patient samples, SALL4 mRNA expression was validated in endometrial carcinoma samples using quantitative reverse transcription PCR (qRT-PCR). As we have previously identified that human SALL4 has two isoforms (SALL4A and SALL4B), 7 isoform-specific primers and Taqman probes were used for qRT-PCR. By qRT-PCR, we established that both isoforms were elevated in a subgroup of primary endometrial cancers compared with normal (Supplementary Figure S1 ).
To examine whether the upregulation of SALL4 has any clinical significance in endometrial carcinoma, we carried out clinicopathological analysis to see whether SALL4 expression predicts poor prognosis. We retrieved clinicopathological and demographic data of 113 endometrial carcinoma cases (Table 1 and Supplementary Table S2 ). We found that SALL4 expression was significantly correlated with poor survival of EC patients (P ¼ 0.05; Figure 1b ).
We next chose to compare our observation with existing published expression database on endometrial cancer. Levan et al. 11 have reported a gene signature that can predict poor prognosis in endometrial carcinoma. We extracted the gene expression profiles and re-analyzed the data in order to examine whether SALL4 was differentially expressed between survivor and non-survivor groups. We found that SALL4 expression was significantly higher in the non-survivor group compared with the survivor group ( Figure 1c ). Furthermore, we carried out Gene Set Enrichment Analysis (GSEA) to investigate whether gene sets that have prognostic values are enriched in SALL4-expressing endometrial carcinomas from the same database. Indeed, in SALL4-expressing endometrial carcinoma, we observed enrichment of gene sets upregulated in cancers with poor survival (Po0.001), metastasis (Po0.001), advanced tumor stage (Po0.001) and proliferation (Po0.001). On the other hand, gene sets that are enriched in cancers with good survival (Po0.001) and downregulated in cancers of advanced stage (Po0.001), proliferation (P ¼ 0.006) and metastasis (P ¼ 0.047) are enriched in SALL4-negative endometrial carcinomas (Figure 1d and Supplementary Figure S2 ).
In summary, these results support that SALL4 expression is significantly correlated with poor survival of endometrial cancer patients.
Silencing of SALL4 inhibits cell growth in vitro and tumorigenicity in vivo as a result of decreased proliferation and increased apoptosis To assess the biological functional role of SALL4 in endometrial cancer, we first evaluated SALL4 expression in a panel of six endometrial cancer cell lines using qRT-PCR to select for appropriate models for our functional studies (Supplementary Figure S3 ). Three cell lines, AN3CA, HEC-1A and Ishikawa, were selected for subsequent studies based on their endogenous SALL4 expression of high, moderate or undetectable levels, which best represented the differential SALL4 expression levels encountered in primary human endometrial cancer tissues. To suppress SALL4 expression in endometrial cancer cells, two short hairpin RNAs (shRNAs) specifically targeting both SALL4A and SALL4B isoforms, designated as SALL4-sh1 and SALL4-sh2, were chosen and optimized from five constructs. AN3CA and HEC-1A cells were infected with lentivirus expressing shRNAs. On day 4 after infection, loss of SALL4 induced substantial cell death in both AN3CA and HEC-1A cells. The changes in cell morphology and apoptotic phenotypes were visible by light microscopy (Figure 2a ). Knockdown efficiency of the two shRNAs was verified by western blotting and qRT-PCR (Figures 2b and c ). Both shRNAs could downregulate SALL4A and SALL4B efficiently in AN3CA and HEC-1A cells.
To elucidate the role of SALL4 in endometrial cancer cell survival, the viability of lentiviral-infected AN3CA and HEC1-A cells was first examined by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay over a period of time. The growth rate of SALL4-knockdown cells was significantly decreased compared with those of scrambled shRNA-treated control cells ( Figure 2d ). In contrast, no significant effect was observed upon SALL4 knockdown in Ishikawa cells, which had undetectable SALL4 expression endogenously (Supplementary Figure S4 ). To further verify that the effects of shRNAs are specific, we prepared SALL4A and SALL4B overexpression constructs that carried triple-point mutation within the 21-bp sequence targeted by SALL4-sh1. These mutations did not lead to an amino-acid sequence change of SALL4 protein but rendered the overexpression constructs insensitive to inhibition by SALL4-sh1 and therefore could be used as rescue mutants to test the specificity of the shRNA. After co-infection of AN3CA cells with SALL4-sh1 and rescue mutant SALL4A or SALL4B lentivirus, we observed that mutant SALL4A alone or SALL4B alone was able to partially rescue SALL4 shRNA-induced phenotype (Supplementary Figure S5) .
The decrease in cell growth could be due to impaired proliferation and/or increased cell death. To determine the effect of SALL4 knockdown on cell proliferation, we measured bromodeoxyuridine (BrdU) incorporation in vitro by flow cytometry. SALL4 knockdown significantly decreased the proportions of BrdU-positive proliferating endometrial cancer cells (Figure 2e ). We next assessed the effect of SALL4 depletion on the apoptotic activity of the endometrial cancer cells using AnnexinV staining. The percentages of Annexin V-positive cells were much higher in SALL4 knockdown groups than the scrambled control groups (Figure 2f ). Collectively, these data suggest that loss of SALL4 inhibits cell proliferation and triggers cell apoptosis in vitro. The oncogenic role of SALL4 in endometrial cancer was further confirmed by using xenograft mouse models. First, a subcutaneous xenograft mouse model was developed to assess the tumor growth rate in vivo. Two million AN3CA cells treated with either scrambled control or SALL4 shRNA-expressing lentiviruses were injected subcutaneously into the right flank region of NOD/SCID mice and monitored for tumor development. As shown in Figures 3a and b, tumor growth induced by the SALL4 knockdown group was dramatically slower than that induced by scrambled shRNAtreated cells. The excised tumors were then subjected to routine histology processing and immunostaining analysis. Cellular proliferation in tumor tissues was assessed by immunostaining with anti-Ki-67 antibody (Figure 3c , right panel). Decreased Ki-67 staining was observed in the small tumors induced by SALL4 The role(s) of SALL4 in endometrial cancer knockdown cells compared with the controls, suggesting that loss of SALL4 could significantly inhibit cell proliferation. On the contrary, subcutaneous tumors induced by SALL4 knockdown cells showed a marked increase in the number of apoptotic cells as detected by terminal uridine deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis (Figure 3c , left panel).
Despite the fact that the subcutaneous xenograft murine model is suitable for monitoring tumor growth locally, this model has limitations in mimicking human endometrial cancer disease progression. Therefore, we also attempted an intraperitoneal xenograft model to assay for the effect of SALL4 downregulation on the tumorigenicity of AN3CA cells. Ten million AN3CA cells treated with either scrambled control or SALL4 shRNA-expressing lentiviruses were injected into the peritoneal cavity of NOD/SCID mice, and the recipients mice were monitored for tumor development and overall health status. Although the scrambled control-treated NOD/SCID recipient mice died of disseminated tumor within 2 months of tumor cell injection, the SALL4 shRNAtreated NOD/SCID recipient mice were still alive at the end of the study. A statistically significant difference in survival was observed between the two groups of mice (Supplementary Figure S6) .
Taken together, these results clearly demonstrate that silencing SALL4 inhibits endometrial cancer cell growth in vitro and tumorigenicity in vivo by inhibiting proliferation and triggering apoptosis. Downregulation of SALL4 decreases the invasiveness of endometrial cancer in vitro and blocks its metastatic potential in vivo Metastasis is a central problem in cancer therapeutics. As our analysis showed a positive correlation between SALL4 expression and endometrial cancer metastasis, we next aimed to assess whether loss of SALL4 could affect tumor invasiveness. In a wound-healing assay, a much slower wound closure rate was observed in the SALL4-knockdown AN3CA and HEC-1A cells as compared with the scrambled shRNA-treated cells (Figure 4a ). In transwell migration and invasion assays, significantly reduced migration and invasion were also observed in AN3CA and HEC-1A cells upon SALL4 knockdown ( Figure 4b ). We then asked whether loss of SALL4 could influence cell migration and metastasis formation in vivo. We compared the invasive potential of AN3CA, HEC-1A and Ishikawa cell lines in vitro and detected a strong association between SALL4 expression and invasive capacity, with Ishikawa showing the least migration/invasion ability.
We next explored the role of SALL4 in endometrial cancer metastasis by using another xenotransplant model. The most invasive cell line with high endogenous SALL4 expression, AN3CA, was chosen for the in vivo metastasis assay. SALL4-knockdown or scrambled shRNA-treated AN3CA cells were injected into NOD/ SCID mice through the retro-orbital route, representing an intravenous xenotransplant model. Metastasis of the tumor in all organs was evaluated 6 weeks later when scrambled shRNA-treated recipient mice became morbid. Five out of the six scrambled shRNA-treated AN3CA recipients had markedly enlarged tumor-bearing livers (Figure 4c Figure S7 ). In contrast, all the SALL4 shRNA-treated AN3CA recipients (n ¼ 9) had no detectable tumors macroscopically or microscopically by routine hematoxylin and eosin examination in any of the organs we evaluated, including liver, kidney ( Supplementary Figure S7) , lung and spleen. Only by staining for green fluorescent protein (GFP), which was used to mark the shRNA-infected tumor cells, we were able to identify a few microscopic clusters of GFP-positive cells in the tissues of SALL4 shRNA-treated recipient mice (Supplementary Figure S8 ). This is in contrast to large GFP-positive tumor nodules in tissue organs observed in scrambled shRNAtreated recipient mice (Supplementary Figure S8) . These data suggest that SALL4 is essential to maintain the invasive state of endometrial cancer cells.
Manipulation of SALL4 expression affects the sensitivity of endometrial cancer cells to carboplatin treatment Drug resistance is another important problem in endometrial cancer patients with advanced stages. We next asked whether SALL4 expression could affect the sensitivity of endometrial Figure S9 ). Furthermore, we observed that both SALL4A-and SALL4B-transfected Ishikawa cells showed increased proliferation after carboplatin treatment compared with empty vector control as demonstrated by Ki-67 staining (Figure 5d ). In addition, SALL4 overexpression could significantly protect cells from apoptosis induced by carboplatin treatment, as assayed by TUNEL staining (Figure 5d ). On the contrary, in carboplatin-resistant HEC-1A cells, knocking down SALL4 significantly restored the sensitivity of these cells to carboplatin treatment (Figures 5e and f) .
In summary, our data suggest that in endometrial cancer upregulation of SALL4 expression can contribute to chemotherapy resistance.
SALL4 directly regulates c-Myc transcriptional activity in endometrial cancer cells To explore the mechanism of SALL4 in endometrial cancer, we focused on its potential downstream target gene(s) known to be involved in cancer metastasis and drug resistance. We have previously performed a genome-wide analysis of SALL4 target genes in myeloid leukemic NB4 cells as well as murine ES cells using chromatin immunoprecipitation followed by microarray on the promoter regions (ChIP-chip) approach. 12, 13 Re-analyzing these ChIPchip data sets, we found that SALL4 could bind to the c-Myc promoter region in these cells (Figure 6a ). It is possible that SALL4 regulates c-Myc in endometrial cancer as well. To test this hypothesis, we verified the ChIP-chip result quantitatively using a regular ChIP coupled with qPCR approach. We demonstrated that SALL4 indeed could bind to the promoter region of c-Myc in AN3CA cells (Figure 6b ). To examine the regulatory effect of SALL4 on c-Myc expression, we performed western blotting and qRT-PCR analysis after SALL4 knockdown in AN3CA and HEC-1A cells. SALL4 silencing in these two cell lines significantly decreased the protein and mRNA expression of c-Myc compared with scrambled control (Figures 6c  and d) . A parallel ectopic SALL4 overexpression experiment was carried out in Ishikawa cells, which have negligible endogenous SALL4 expression. As shown in Figures 6c and e, both SALL4A and SALL4B overexpression could significantly increase c-Myc protein and mRNA expression. These data suggest that SALL4 can directly regulate c-Myc in endometrial cancer. 
DISCUSSION
It has been proposed that human pre-implantation embryonic cells share similar phenotypes with cancer cells. Both types of cells are at a proliferative stem/undifferentiated cell state and are potentially immortal. Furthermore, cancer with an ES cell gene expression signature has poor prognosis. 3 We and others have shown that Sall4 is a key factor of the transcriptional core network essential for the maintenance of the stemness of ES cells. 14, 15 SALL4 is also abnormally expressed in germ cell tumors and has been proposed as a diagnostic marker for these tumors. 8 However, more comprehensive and systematic studies on the functional role(s) of SALL4 in human solid tumors such as endometrial cancer are still lacking. In this study, we set out to test our hypothesis that SALL4 is reexpressed in solid cancer cells and contributes to cancer cell tumorigenic properties, focusing on the endometrial cancer model. Our study suggests that SALL4 is re-expressed in almost half of the endometrial cancers at both the mRNA and protein levels, but not in the pre-neoplastic endometrial hyperplasia or normal endometrial tissues. More importantly, our clinical data combined with GSEA analysis also support that aberrant SALL4 expression is positively correlated with aggressive tumor features, including worse survival, increased metastasis and advanced tumor stages. Using gain-and loss-of-functional studies, we further confirmed the essential role of SALL4 in cancer cell survival, metastasis and drug resistance of endometrial cancer. Indeed, from our immunohistochemistry (IHC) study, we observed elevated SALL4 expression in 47.7% of endometrial carcinoma (n ¼ 113) were positive for SALL4 expression ( Supplementary Table S1 ).
The ability of tumor cells to acquire metastatic potential and spread in their host organism is one of the main issues in cancer treatment, as metastasis accounts for 490% of human cancerrelated deaths. 16 Our correlation study on SALL4 expression and other clinicopathological characteristics of the endometrial cancer patients reveals a positive correlation between high SALL4 expression and poor patient survival, and our GSEA data have suggested that SALL4 is positively correlated with tumor metastatic capacity in addition to poor patient survival. Furthermore, both our in vitro cell culture and in vivo murine data have confirmed that SALL4 expression is critical for tumor invasive capacity, metastatic ability and survival of the xenotransplant recipient mice. This suggests that SALL4 can be a potential therapeutic target, and blocking the oncogenic role of SALL4 could potentially benefit patients with more advanced endometrial cancer, whose prognosis are very poor in general with a median survival of o1 year. 17 Future studies are needed to test this potential.
Another challenging hurdle in cancer therapy is chemoresistance. C-Myc is frequently overexpressed in a wide range of human cancers, including endometrial carcinoma. [18] [19] [20] In addition, the role of c-Myc in tumor metastasis and drug resistance has been extensively studied. [21] [22] [23] [24] In this report, we have demonstrated that c-Myc is one of the SALL4 target genes by ChIP-qPCR assay. Furthermore, our loss-and gain-of-function studies have shown that c-Myc expression level is regulated directly by SALL4, and manipulation of SALL4 expression can affect drug sensitivity of endometrial cancer cells. Therefore, we propose that c-Myc is one of the key target genes of SALL4 in endometrial cancer, which could contribute, at least in part, to SALL4-mediated metastasis and drug resistance. As SALL4 is also involved in leukemia and other solid tumors, it is will be interesting to test whether the SALL4/c-Myc pathway could be a general property of SALL4-mediated tumorigenesis.
In summary, our study has revealed the following novel and important findings: (I) SALL4 is not expressed in normal or hyperplastic endometrial but is aberrantly expressed in 47.7% of endometrial carcinoma, and its expression was positively correlated with aggressive tumor features; and (II) SALL4 is critical for endometrial cancer cell survival, drug resistance and tumor progression. As a consequence of being an oncofetal protein with functional roles in cancer cell and absence in normal tissue, SALL4 represents an attractive novel drug target for the high-risk endometrial cancer patient population, similar to what we have reported for aggressive hepatocellular carcinomas. 25 Overall, our finding provides a novel insight into the mechanism and potential therapeutic target for endometrial cancer patients.
MATERIALS AND METHODS

Patient samples
Twenty-one cases of normal endometrial tissues, 5 cases of endometrial hyperplasia and 113 cases of endometrial carcinoma tissues from the Brigham and Women's Hospital, Boston, MA, USA and the National University Hospital of Singapore were selected for the study. Ethics approval was obtained from the Brigham and Women's Hospital Institutional Review Board (2011-P-000096/1) as well as from the National University of Singapore Institutional Review Board (NUS IRB 09-261).
SALL4 IHC analysis
IHC staining was performed according to the standard techniques. Briefly, paraffin tissue sections of 4 mm were deparaffinized with Histoclear and hydrated in graded ethanols. Antigen retrieval was performed by boiling at 120 1C in high pH target retrieval solution for 10 min in a pressure cooker. Primary antibodies were incubated at room temperature for 1 h in a humidified chamber, followed by HRP-conjugated secondary antibody incubation for 30 min at room temperature. Antibody binding was revealed by 3,3 0 diaminobenzidine, and the reaction was stopped by immersion of tissue sections in distilled water once brown color appeared. Tissue sections were counterstained by hematoxylin, dehydrated in graded ethanol and mounted. Monoclonal anti-SALL4 antibody (Santa Cruz Inc., Santa Cruz, CA, USA; No. SC-101147) was used. All reagents for IHC were from Dako (Dako Denmark A/S, Glostrup, Denmark). Appropriate positive and negative controls were included for each run of IHC. For IHC on tissue microassays, SALL4 expression was scored according to the percentage of The role(s) of SALL4 in endometrial cancer A Li et al tumor cells stained positive for SALL4, with 0 denoting o5% of tumor cells stained, þ 1 denoting 5-30% of tumor cells stained, þ 2 denoting 31-50% of tumor cells stained and þ 3 denoting 51-80% of tumor cells stained.
Lentiviral constructs and lentivirus generation
Human SALL4A or SALL4B fragments were subcloned into a modified lentiviral vector (FUW-Luc-mCh-puro) with mCherry and puromycin selection markers (Supplementary Figure S5a ). SALL4A or SALL4B mutant preserving the same amino-acid sequence but containing triple-point mutations within the SALL4shRNA1 target nucleotide sequence, which renders the transgenes resistant to SALL4 shRNA targeting, were generated using QuikChange site-directed mutagenesis kit Stragagene (La Jolla, CA, USA) and confirmed by sequencing. shRNAs set for human SALL4 in pLKO.1-puro vector were purchased from Open Biosystem, Pittsburgh, PA, USA (RHS3979), and knockdown efficiency was further evaluated. Two of them, designated as SALL4shRNA1 and SALL4shRNA 2, were selected for subsequent experiments. The sequences for SALL4 shRNAs and scrambled shRNA are listed as following: SALL4shRNA1: 5 0 -GCCTTGAAACAAGCCAAGCTA-3 0 ; SALL4shRNA 2: 5 0 -CTATTTAGCCAAAGGCA AA-3 0 ; and Scr-shRNA: 5 0 -CCTAAGGTTAAGTCGCCCTCG-3 0 .
Cell culture
Cell lines AN3CA, HEC-1A and KLE were kindly provided by Dr Patricia Donahoe (Massachusetts General Hospital, Boston, MA, USA). 26 
Wound-healing, migration and invasion assays
An artificial 'wound' was created on a confluent cell monolayer, and photographs were taken at the indicated time. A permeable filter of transwell system (8-mm pore size, Transwell Permeable supports, Cat. No. 3422, Corning Incoporated, Tewksbury, MA, USA) was used for migration assays and 24-well plates with Matrigel-coated inserts (8-mm pores; BD Biosciences, San Jose, CA, USA) were used for matrigel invasion assays. After puromycin selection, shRNAs-infected cells were added to inserts in accordance with the manufacturer's protocol. Cells were incubated for the indicated time periods under standard culture conditions. Tumor cells remaining on the top side of the membrane were removed by cotton swab. Cells that migrated to the underside were fixed and stained with crystal violet solution. After taking pictures, the stained cells were solubilized with 10% acetic acid and quantitated on a microplate reader at 600 nm.
Xenotransplant murine models
All experimental procedures involving animals were conducted in accordance with the institutional guidelines set forth by the Children's Hospital Boston (CHB animal protocol number 11-09-2022). Eight-to-10-
week-old NOD/SCID mice were housed in a specific pathogen-free facility.
To generate a subcutaneous xenograft mouse model, NOD/SCID mice were injected subcutaneously with 2 Â 10 6 cells into the right flanks. Cells were resuspended in 0.1 ml of phosphate-buffered saline and then mixed with 0.1 ml of matrigel. Tumor sizes were measured weekly. For the development of intraperitoneal-injected xenograft model, 10 million cells, suspended in 500 ul of phosphate-buffered saline, were injected with a 25-gauge needle into the peritoneal cavity of NOD/SCID mice, and disease progression was monitored based on overall health status of the recipient mice. As for the metastatic mouse model, one million 1 Â 10 6 AN3CA cells were injected via the retro-orbital sinus route as a method of intravenous xenotransplant model described previously. After 6 weeks, mice were euthanized, and organs were checked for metastasis. 28 Tissues of the liver, lung, spleen and kidney were collected and fixed in 10% neutral-buffered formalin for further routine histology examination by hematoxylin and eosin stain.Tissue sections were also stained with anti-GFP antibody (Abcam, Cambridge, MA, USA, Cat. No. ab6556). The antibody was utilized at 1:400 in a Leica Bond-III autostainer (Bond-Max, Leica, Buffalo Grove, IL, USA) using the Bond Polymer Refine Detection Kit (Leica Microsystems Inc., Bannockburn, IL, USA) according to manufacturer's protocol. Cell proliferation in the tumors was determined by staining histological sections with monoclonal antibody against Ki-67 (BD Biosciences, Cat. No. 556003), and apoptosis was evaluated by TUNEL assay (In Situ Cell Death Detection Kit, Promega, Madison, WI, USA, Cat. No. G3250) according to the manufacturer's protocol.
Cell proliferation and apoptosis
Cell proliferation was monitored by the MTS assay as described, 29 and BrdU incorporation assay. The BD Pharmingen BrdU flow kit (BD Biosciences) was used. BrdU was added up to 1 h before harvesting of cells, and incorporation to the cells was assessed according to the manufacturer's instructions. Simultaneous staining of DNA with 7-aminoactinomycin D was used in combination with BrdU, followed by two-color flow cytometric analysis. Apoptosis was assayed by AnnexinV kit following a protocol from the supplier (BD Biosciences).
qChIP (chromatin immunoprecipitation) and qRT-PCR AN3CA cells were grown and processed for qChIP as described previously 30 using an anti-SALL4 antibody. Real-time PCR was performed with two sets of c-Myc primers ( Supplementary Table S3 ) to validate pulldown DNA fragment. Normal immunoglobulin G was used as a negative control. Total RNA was extracted with Trizol reagent (Invitrogen) or RNeasy kit Qiagen (Valencia, CA, USA). Real-time PCR for SALL4A and SALL4B was performed with the TaqMan PCR core reagent kit Applied Biosystems (Foster City, CA, USA) as described previously. 7 C-Myc mRNA expression was measured using iScript One-step RT-PCR Kit with SYBR Green (Bio-Rad). C-Myc primers are as follows: forward 5 0 -TCAAGAGGCGA ACACACAAC-3 0 ; and reverse: 5 0 -GGCCTTTTCATTGTTTTCCA-3 0 .
GSEA analysis
Gene expression data of endometrial carcinoma was extracted from the GEO database (accession number: GSE21882). Before GSEA, all EC samples were divided into two groups according to their SALL4 expression: SALL4 high and SALL4 low. GSEA was then performed based on normalized data using GSEA v2.0 tool (http://www.broad.mit.edu/gsea/) for identification of enriched gene sets between the SALL4 high and SALL4 low groups.
Chemoresistance assay
Carboplatin was purchased from Sigma (Sigma-Aldrich, Cat. No. C2538). Cultured cells were plated in six-well plates to allow for colony formation for 2-3 weeks, or cells were seeded on coverslips overnight. Then, cells were treated with the indicated dosages of carboplatin for 72 h. Cell proliferation and apoptosis were evaluated by MTS assay, Ki-67 staining or TUNEL assay, respectively, as described above.
Statistical analysis
Results are expressed as mean±s.d. from at least three independent experiments. Statistical significance between the two groups was determined by Student's t-test or Pearson's chi-squared test (w 2 ) test (GraphPad Prism 5.0 software (La Jolla, CA, USA)). Log-rank test was used for survival analysis. The value of Po0.05 was considered significant and is indicated by an asterisk.
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